View Post

Aspirin may help some breast cancer survivors, but changes in DNA may mean harm for others

In In The News by Barbara Jacoby

Source: University of North Carolina at Chapel Hill From: sciencedaily.com Chemical changes in DNA — called methylation — in blood and breast cancer tumors may modify aspirin’s role in mortality risk Previous studies have shown that some women who use aspirin and are later diagnosed with breast cancer may live longer, which may be related to the drug’s anti-inflammatory effects …

View Post

Nearly Three in Five U.S. Women Do Not Know There Is a Difference Between Cosmetic Surgeons and Plastic Surgeons

In In The News by Barbara Jacoby

Source: PR Newswire From: finance.yahoo.com – More than one in four women in the U.S. are currently considering a cosmetic procedure; among those currently considering a procedure, 73 percent have never had one in the past – Nearly three in five women in the U.S. do not know there is a difference between a cosmetic surgeon and plastic surgeon – …

View Post

Scientists Successfully Turn Breast Cancer Cells Into Fat to Stop Them From Spreading

In Clinical Trials by Barbara Jacoby

By: JACINTA BOWLER From: sciencealert.com Researchers have been able to coax human breast cancer cells to turn into fat cells in a new proof-of-concept study in mice. To achieve this feat, the team exploited a weird pathway that metastasising cancer cells have; their results are just a first step, but it’s a truly promising approach. When you cut your finger, …

View Post

NICE approves drug with potential to prevent breast cancer return

In In The News by Barbara Jacoby

By: Jo Stephenson From: nursingtimes.net The National Institute for Health and Care Excellence published draft guidance recommending the drug neratinib as an extra treatment for a form of HER2-positive breast cancer. HER2-postitve breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer …

View Post

Personalized assay surpasses limits for detecting tumor DNA in breast cancer patients

In In The News by Barbara Jacoby

Source: American Association for the Advancement of Science From: eurekalert.org Scientists have developed a personalized platform tailored to patients’ specific cancer mutations named TARDIS, which was able to accurately detect circulating tumor DNA (ctDNA) and signs of residual disease in 33 women with breast cancer. Their technology demonstrated a hundredfold improvement in sensitivity compared to previous approaches. Although more testing …

View Post

Where Does T-DM1 Fit In First-Line Treatment for HER2-Positive Breast Cancer?

In Clinical Trials by Barbara Jacoby

By: Dave Levitan From: www.cancernetwork.com Trastuzumab emtansine (T-DM1) with or without pertuzumab yielded good overall survival in patients with HER2-positive metastatic breast cancer according to the results of a phase III trial published in Cancer. Though these were not superior to survival seen with taxane-based therapy, T-DM1 should be considered an option for first-line therapy in patients deemed unsuitable for …

View Post

21st Century Oncologist Part of a Study that Gives Older Women More Options for Breast Cancer Treatment

In In The News by Barbara Jacoby

Source: PR Newswire From: ptcommunity.com A newly published report—co-authored by Dr. Frank Vicini, principal investigator at 21st Century Oncology, and several oncologists from leading medical institutions—finds that older women with low-risk, hormone-positive breast cancer can safely opt for a short dose of radiation instead of taking anti-estrogen pills, which can cause adverse side effects like hot flashes, weight gain and …

View Post

Newer Treatments and Combinations Emerging for Breast Cancer Brain Metastases

In Clinical Trials by Barbara Jacoby

By: Dylann Cohn-Emery From: targetedonc.com Multiple treatment options are emerging for patients with breast cancer that has metastasized to the brain, looking to improve upon the standards of care for patients with breast cancer–related brain metastases (BM) across breast cancer subtypes. A phase II study looking at abemaciclib (Verzenio), a CDK4/6 inhibitor, in patients with HR-positive, HER2-negative metastatic breast cancer …